Evaluation of novel and superior formulation CaroTexTM developed by Biofusion Technology
Per WHO, vitamin A deficiency is a systemic disease affecting cells, organs throughout the body. The gradual depletion of vitamin A stores results in xerophthalmia, night blindness, xerosis etc., reversed by vitamin A therapy. Beta-Carotene, a carotenoid, is the precursor of vitamin A, which cannot be synthesized by the human body. Hence beta carotene formulation has gathered considerable attention in the healthcare industry. Hydrophobicity of Beta carotene being a major challenge in the formulation, Zeushygia Life Sciences Pvt. Ltd (Telangana India) developed a novel beta carotene formulation, CaroTex, with enhanced bioavailability. The present study assesses the bioavailability of CaroTex in a rodent model. The animals were divided into 5 groups, Normal Control, Vehicle Control, Standard beta Carotene, Comparator and CaroTex. As rats efficiently convert beta carotene into vitamin A, high dose of beta-carotene (50mg/kg) was given orally for 7 consecutive days. Beta carotene, its metabolic product retinal were measured in rat liver. It was observed that beta carotene concentration in rats fed with CaroTex was about 1.70, 2.55 times higher than Comparator and control respectively whereas the concentration of retinal was the same in all groups. It is evident from this study that novel formulation technology (BioFusion Technology) of CaroTex reflects in relatively higher concentration levels of beta carotene.
PDF Downloaded: 29 LaTeX Downloaded: 4 HTML Downloaded: 0 ePUB Downloaded: 5
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.